Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?
A Marrelli, P Cipriani, V Liakouli, F Carubbi… - Autoimmunity …, 2011 - Elsevier
Angiogenesis is the formation of new blood vessels from existing vessels. During RA new
blood vessels can maintain the chronic inflammatory state by transporting inflammatory cells to …
blood vessels can maintain the chronic inflammatory state by transporting inflammatory cells to …
[HTML][HTML] Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study
…, P Ruscitti, O Berardicurti, I Pantano, V Liakouli… - Arthritis research & …, 2013 - Springer
Introduction Primary Sjögren’s syndrome (pSS) is an autoimmune disorder affecting
exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular …
exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular …
[HTML][HTML] The Role of IL-1β in the Bone Loss during Rheumatic Diseases
P Ruscitti, P Cipriani, F Carubbi, V Liakouli… - Mediators of …, 2015 - hindawi.com
Several inflammatory diseases have been associated with increased bone resorption and
fracture rates and different studies supported the relation between inflammatory cytokines and …
fracture rates and different studies supported the relation between inflammatory cytokines and …
[HTML][HTML] Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers
Background Adult-onset Still’s disease (AOSD) is rare inflammatory disease of unknown
etiology that usually affects young adults. The more common clinical manifestations are spiking …
etiology that usually affects young adults. The more common clinical manifestations are spiking …
Methotrexate: an old new drug in autoimmune disease
P Cipriani, P Ruscitti, F Carubbi, V Liakouli… - Expert Review of …, 2014 - Taylor & Francis
Methotrexate (MTX) is currently considered, among disease-modifying anti-rheumatic drugs
(DMARDs), the ‘anchor-drug’ in the treatment of rheumatoid arthritis. In the last 25 years, …
(DMARDs), the ‘anchor-drug’ in the treatment of rheumatoid arthritis. In the last 25 years, …
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis
M Manetti, L Ibba-Manneschi, V Liakouli… - Annals of the …, 2010 - ard.bmj.com
Background Early endothelial cell (EC) activation/damage and profibrotic Th2-associated
cytokines play a pivotal role in systemic sclerosis (SSc). Interleukin 33 (IL33) is a novel …
cytokines play a pivotal role in systemic sclerosis (SSc). Interleukin 33 (IL33) is a novel …
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid …
…, S Gandolfo, M Gatto, RD Grembiale, V Liakouli… - Autoimmunity …, 2017 - Elsevier
Autoimmune diseases are a complex set of diseases characterized by immune system
activation and, although many progresses have been done in the last 15 years, several unmet …
activation and, although many progresses have been done in the last 15 years, several unmet …
Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis
…, M Gerosa, M Gilio, G Guggino, V Liakouli… - Autoimmunity …, 2019 - Elsevier
Autoimmune rheumatic diseases are characterised by an abnormal immune system response,
complement activation, cytokines dysregulation and inflammation. In last years, despite …
complement activation, cytokines dysregulation and inflammation. In last years, despite …
[HTML][HTML] Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
…, M Frassi, B Frediani, D Iacono, V Liakouli… - PLoS …, 2019 - journals.plos.org
Background The inflammatory contribution to type 2 diabetes (T2D) has suggested new
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we …
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we …
Interstitial lung disease in systemic sclerosis: current and future treatment
R Giacomelli, V Liakouli, O Berardicurti… - Rheumatology …, 2017 - Springer
Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and
is characterized by vascular damage, inflammation and fibrosis of the skin and various …
is characterized by vascular damage, inflammation and fibrosis of the skin and various …